4-oxo-4-(3-pyridyl)butanoic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
4-oxo-4-(pyridin-3-yl)butanoic acid : A monocarboxylic acid that is succinic acid in which the hydroxy group of one of the carboxy groups is replaced by a pyridin-3-yl group. A byproduct of tobacco-specific N-nitrosamines generated by cytochrome P-450 which catalyzes methylnitrosaminopyridylbutanone hydroxylation, this nicotine metabolite is commonly found in the urine of smokers. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 437 |
| CHEMBL ID | 3544790 |
| CHEBI ID | 66951 |
| SCHEMBL ID | 2638149 |
| MeSH ID | M0302000 |
| Synonym |
|---|
| HMS1701M19 |
| BB 0258407 |
| unii-8y4ex5xj5b |
| gamma-oxo-3-pyridinebutanoic acid |
| 8y4ex5xj5b , |
| 4-oxo-4-(3-pyridyl)butanoic acid |
| 4-oxo-4-pyridin-3-yl-butyric acid |
| AKOS000300287 |
| 4192-31-8 |
| 4-oxo-4-pyridin-3-ylbutanoic acid |
| STK689348 |
| 4-oxo-4-(pyridin-3-yl)butanoic acid |
| 3-succinoylpyridine |
| C19569 |
| g-oxo-3-pyridinebutyric acid |
| 4-oxo-4-(3-pyridyl)butyric acid |
| 3-pyridinebutanoic acid, gamma-oxo- |
| 1-(3-pyridyl)-1-butanone-4-carboxylic acid |
| FT-0673393 |
| 4-oxo-4-(3-pyridyl)-butanoic acid |
| 4-oxo-4-(pyridin-3-yl)butyric acid |
| CHEBI:66951 , |
| 4-oxo-4-(3-pyridyl)-butyric acid |
| gamma-oxo-3-pyridinebutyric acid |
| AB01331602-02 |
| SCHEMBL2638149 |
| JGSUNMCABQUBOY-UHFFFAOYSA-N |
| gamma-oxo-3-pyridinebutanoate |
| 4-oxo-4-(3-pyridyl)-butanoate |
| CHEMBL3544790 |
| mfcd00870737 |
| NCGC00338261-01 |
| 4-oxo-4-(3-pyridyl)-butanoic acid (opba) |
| Q27135538 |
| AS-10189 |
| SB37120 |
| opba |
| 3-pyridinebutanoic acid, .gamma.-oxo- |
| .gamma.-3-pyridyl-.gamma.-oxobutyric acid |
| .gamma.-oxo-3-pyridinebutanoic acid |
| DTXSID60863335 |
| 4-(pyrid-3-yl)-4-oxo-butyricacidhydrochloride |
| ?-oxo-3-pyridinebutyric acid |
| discontinued. please see o859160 |
| EN300-134219 |
| CS-0233523 |
| gamma-oxo-3-pyridinebutyric acid, n-hydroxysuccinimide ester |
| 4-oxo-4-(pyridin-3-yl)butanoicacid |
| Z838955798 |
| Class | Description |
|---|---|
| pyridines | Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives. |
| monocarboxylic acid | An oxoacid containing a single carboxy group. |
| aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||